The overexpression of CTLA-4 by iTregs, which, upon interaction with CD80/CD86 on dendritic cells, could suppress T lymphocyte activation or induce anergy in effector T cells, thereby diminishing anti-tumor immunity. This evidence concerns the gene CTLA4 and neoplasm.